efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg. - LARVOL DELTA

Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial. (PubMed, Lancet Reg Health Southeast Asia) - "We aimed to compare the virological and metabolic outcomes after switching from TDF/FTC/EFV to TDF/3TC/DTG or TDF/FTC plus RPV. This work was supported by The Royal College of Physicians of Thailand, (to R.K.). APC fee was supported by Faculty of Tropical Medicine, Mahidol University and Mahidol University (to T.N.)."

Head-to-Head • Journal • Human Immunodeficiency Virus • Infectious Disease

Antiretroviral therapy regimens initiated during pregnancy and risks of adverse perinatal outcomes. (PubMed, AIDS) - "Our observational study findings for the composite outcome were comparable to the IMPAACT 2010/VESTED trial in a real-world programmatic setting and enabled evaluation of additional regimen and broader set of outcomes. In settings where randomized trial data are limited, well designed observational emulations of trials using nonrandomized data can provide informative evidence. As Botswana expands use of TAF in pregnancy, these results provide reassuring evidence supporting its safety."

Adverse events • Journal • Human Immunodeficiency Virus • Infectious Disease • Small for Gestational Age

Engagement in care and viral load outcomes in the first 6 months after ART initiation: evidence from 18 South African clinics (AIDS 2026) - "Most initiated TDF/FTC/EFV (56%) or TDF/3TC/DTG (42%)...Initiation on dolutegravir-containing regimens was associated with higher suppression rates than efavirenz-containing regimens (aRR 1.14, 95% CI 1.09-1.19)... Continuous engagement in the early treatment period, without interruptions >28 days, increased the likelihood of VL suppression at 6 months. Observational data suggest that suppression improved markedly between 2018 and 2023, potentially due to changes in treatment regimens, earlier VL testing, and/or other service delivery improvements. Programs should prioritize preventing even short treatment interruptions during the early treatment period and continue innovating service delivery approaches."

Human Immunodeficiency Virus • Infectious Disease • CD4

Optimization to INSTIs in Mexico: retrospective cohort at 144 weeks (AIDS 2026) - "The purpose of our study is to evaluate the proportion of patients who remained virologically suppressed (<50 HIV-1 RNA copies/mL) when switched to Efavirenz/Emtricitabine/Tenofovir disoproxil succinate (EFV/FTC/TDS) as compared to those switched to Bictegravir/Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) at 96 and 144 weeks after optimization. This study reflects that switching to BIC/FTC/TAF in PLHIV with virological suppression results in a higher proportion of undetectability at 96 and 144 weeks, compared to those switched to EFV/FTC/TDS. While staying on EFV/FTC/TDS may represent a potential public health cost saving, the initial economic advantage could later be overshadowed by the expenses incurred in treating individuals who develop virological failure over time."

Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. (PubMed, J Antimicrob Chemother) - P4 | "A three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate maintained durable long-term viral suppression, while mitigating but not fully preventing toxicities associated with EFV/TDF/FTC. These findings support reduced-exposure antiretroviral therapy and warrant evaluation of similar strategies with modern integrase inhibitor-based regimens."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Oncology • Renal Disease • CD4 • CD8

Advanced coronary artery disease in a low-risk HIV patient – a case for early statin intervention (EACS 2025) - "His antiretroviral regimen initially was Kivexa and Efavirenz, which was then switched to Atripla in 2020 and switched to Descovy and Efavirenz in 2022. This case reinforces the inadequacy of relying solely on traditional risk scores for cardiovascular risk assessment in People Living With HIV(PLWH). Chronic inflammation and endothelial dysfunction associated with HIV infection may drive atherosclerosis independently of classical risk factors. In alignment with the REPRIEVE study outcomes, the BHIVA now recommends initiating statins in PLWH based on Q-Risk, advocating for early, primary preventive cardiovascular management in this population."

Clinical • Metastases • Human Immunodeficiency Virus • Infectious Disease • CD4

Virological failure with NNRTI resistance on CAB+RPV-LA in a man with subtherapeutic cabotegravir levels (EACS 2025) - "He achieved sustained virological suppression (HIV-RNA 10 years on oral ART (TDF/FTC/EFV, then TDF/3TC/DOR)...Oral TAF/FTC/DRV/c was briefly initiated but stopped once the subsequent HIV-RNA measurement was <50 c/mL and HIV-DNA sequencing showed no RAMs... This case suggests a potential influence of injection technique and illustrates how retrospective TDM can help elucidate pharmacological contributors to virological failure on long-acting injectables. TDM may assist clinical decision-making in selected cases and inform real-world optimisation strategies."

Human Immunodeficiency Virus • Infectious Disease • CD4

Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide from NNRTI-based ART in virologically suppressed people with HIV (PWH): a retrospective analysis (DRIVE-SWITCH study) (EACS 2025) - "Purpose : Large real-world data in people with HIV (PWH) switching from non-nucleoside reverse transcriptase inhibitors (NNRTIs), especially from rilpivirine (RPV)-based regimens to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) are lacking...Results : Overall, 250 PWH were included: median age 59 years (interquartile range, IQR 51-65); 65 (26%) females at birth, 213 (85%) Italian natives; 141 (56%) switched from RPV/FTC/TAF, 7 (2.8%) from RPV/FTC/TDF, 96 (38.4%) from EFV/FTC/TDF, 3 (1.2%) from NVP+TDF/FTC, 2 (0.8%) from DOR/3TC/TDF, 1 (0.4%) from NVP+TAF/FTC...Treatment discontinuations were rare events. No resistance mutations detected."

Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Model After Continuing or Switching to a Doravirine-Based HIV Treatment Regimen. (PubMed, J Acquir Immune Defic Syndr) - P3 | "After ∼4 years, DOR-based regimens were not associated with changes in ASCVD risk scores in PLWH. Given the increased burden of HIV-associated ASCVD, DOR may represent a therapeutic option that does not increase ASCVD risk."

Journal • Atherosclerosis • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease

Current status of antiretroviral treatment for people living with human immunodeficiency virus in Burkina Faso in the era of the World Health Organization's "test and treat" strategy (PubMed, Med Trop Sante Int) - "The main treatment combination used in adults was TDF/FTC/EFV, accounting for 42% in 2018, 50% in 2019, and 38% in 2020. The TDF/3TC/EFV combination was dominant in 2021, accounting for 46%. In 2022 and 2023, the TDF/3TC/DTG combination was the most common, at 76% in 2022 and 91% in 2023...The proportion of people on ART has gradually increased since the WHO's "test and treat" recommendations. These results bring Burkina Faso closer to achieving the UNAIDS targets."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Exploring the synergistic potential of Atripla® in mitigating the combined effects of protein malnutrition and chronic alcohol intake on rat epididymis (IAS-HIV 2025) - "Atripla®, ethanol and/or protein malnutrition are risks for epididymal tissue derangements. However, the effect of Atripla® was mild and protective of the impact of ethanol and protein malnutrition. This shows success of single-pill therapy in mitigating adverse effects and warrants further investigation."

Preclinical • Fibrosis • Human Immunodeficiency Virus • Immunology • Infectious Disease • Infertility • Sexual Disorders • AR

Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from efavirenz/emtricitabine/tenofovir disoproxil (EFV/FTC/TDF) in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study). (PubMed, Int J Infect Dis) - "Our data showed that BIC/FTC/TAF demonstrated high virologic and immunologic efficacy and excellent safety profile."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8

A combined prospective and retrospective comparative study evaluating renal outcomes after switching from TDF + FTC + EFV to TDF/3TC/DTG (TLD) vs. DTG + 3TC in virologically suppressed Thai people with HIV. (PubMed, HIV Res Clin Pract) - "As a result, people with HIV in Thailand on TDF/FTC/EFV are switched to TLD...Dual therapy with DTG + 3TC may be a preferred switching option over TLD for individuals with renal safety concerns. Further randomized prospective trials with longer follow-up are warranted to confirm these findings."

Clinical • Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • CD4

Depression, Sleep, and Anxiety Among Pregnant and Postpartum Women Using Dolutegravir and Efavirenz (CROI 2025) - "Methods In IMPAACT 2010, pregnant people with HIV were randomized to DTG + emtricitabine (FTC)/tenofovir alafenamide (TAF), DTG+FTC/tenofovir disoproxil fumarate (TDF), or EFV/FTC/TDF arm at 14-28 weeks' gestation and were followed through 50 weeks postpartum. Conclusions This study showed a similar proportion of depression, anxiety, and sleep disturbances between DTG and EFV, with roughly one in five women experiencing postpartum depression across all ART regimens. These findings highlight the importance of screening for mental distress in pregnant people living with HIV and considering postpartum well-being."

Clinical • CNS Disorders • Depression • General Anxiety Disorder • Human Immunodeficiency Virus • Infectious Disease • Mental Retardation • Mood Disorders • Postpartum Depression • Psychiatry • Sleep Disorder

Bone mineral content, growth, and renal health of infants with perinatal exposure to maternal dolutegravir vs efavirenz and tenofovir disoproxil fumarate vs tenofovir alafenamide: the randomized IMPAACT 2010 (VESTED) trial. (PubMed, J Acquir Immune Defic Syndr) - "It is reassuring that maternal DTG-based ART during pregnancy and breastfeeding was associated with higher infant spine bone mineral content, better growth, and less stunting than EFV/FTC/TDF."

Journal • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Obesity

Viral blips in the doravirine phase III clinical trials DRIVE‐FORWARD and DRIVE‐AHEAD (HIV-Glasgow 2024) - "Summary of viral blips in DRIVE-FORWARD and DRIVE-AHEAD DRIVE-FORWARD (1439-018) DRIVE-AHEAD (1439A-021) Double-blind phase (day 1–week 96) DOR + 2NRTIs, n (%) DRV/r + 2NRTIs, n (%) DOR/3TC/TDF, n (%) EFV/FTC/TDF, n (%) Participants in population 342 338 336 322 Total # of blips 42 56 54 46 Participants with blips 38/42 (11.1) 52/338 (15.4) 40/336 (11.9) 39/322 (12.1) With 1 blip 35 (92.1) 48 (92.3) 28 (70.0) 35 (89.7) With 2 blips 2 (5.3) 4 (7.7) 10 (25.0) 3 (7.7) With 3 or more blips 1 (2.6) 0 (0.0) 2 (5.0) 1 (2.6) Months to first blip, median (IQR)a 11.2 (5.4−16.6) 8.5 (5.5−16.7) 13.9 (6.2−18.3) 11.1 (8.3−16.6) Virological failure after blip 8/342 (2.3) 7/338 (2.1) 5/336 (1.5) 3/322 (0.9) Open-label extension (week 100–192) Continued DOR + 2NRTIs Switched to DOR + 2NRTIs Continued DOR/3TC/TDF Switched to DOR/3TC/TDF Participants in population 253 225 286 265 Total # of blips 14 22 20 24 Participants with blips 14/253 (5.5) 17/225 (7.6) 19/286 (6.6) 21/265 (7.9) With 1..."

Clinical • P3 data • Human Immunodeficiency Virus • Infectious Disease • CD4

Comparison of treatment‐emergent resistance associated mutations among single tablet regimens and cabotegravir+rilpivirine for the treatment of virologically suppressed people with HIV: a systematic literature review and network meta‐analysis (HIV-Glasgow 2024) - "Pooled estimates for risk of TE-RAMs at 48 weeks (RR [95% CI]) B/F/TAF 0.45 (0.05−4.34) CAB+RPV Q4W 0.20 (0.02−1.83) 0.44 (0.16−1.22) CAB+RPV Q8W 0.34 (0.00−30.94) 0.76 (0.01−79.65) 1.74 (0.02−186.99) D/C/F/TAF 0.99 (0.02−49.69) 2.21 (0.02−205.13) 5.04 (0.06−458.15) 2.90 (0.01−1134.89) DTG+2NRTIs 0.35 (0.01−12.32) 0.78 (0.02−28.74) 1.78 (0.05−69.14) 1.03 (0.01−163.78) 0.35 (0.00−70.41) DTG/3TC 1.00 (0.02−50.04) 2.23 (0.02−206.57) 5.08 (0.06−461.38) 2.92 (0.01−1142.90) 1.01 (0.00−256.15) 2.85 (0.01−566.10) DTG/ABC/3TC 0.35 (0.00−31.65) 0.79 (0.01−81.51) 1.80 (0.02−191.35) 1.04 (0.00−261.33) 0.36 (0.00−138.70) 1.01 (0.01−159.53) 0.35 (0.00−137.72) DTG/RPV 0.26 (0.03−2.01) 0.58 (0.08−4.41) 1.31 (0.15−11.17) 0.75 (0.01−54.12) 0.26 (0.00−21.66) 0.73 (0.04−14.89) 0.26 (0.00−21.51) 0.73 (0.01−51.62) E/C/F/TXF 0.10 (0.01−1.81) 0.22 (0.01−4.52) 0.49 (0.02−10.90) 0.28 (0.00−26.61) 0.10 (0.00−12.98) 0.28 (0.01−5.57) 0.10 (0.00−12.89) 0.27 (0.00−25.40) 0.37 (0.04−3.95) EFV/FTC/TDF..."

Retrospective data • Review • Human Immunodeficiency Virus • Infectious Disease

Long‐term efficacy and safety of a maintenance 3‐day‐per‐week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate (HIV-Glasgow 2024) - P4 | "Three-day-per-week efavirenz/emtricitabine/tenofovir-disoproxil-fumarate as a maintenance therapeutic strategy was effective in the long-term and deferred toxicity."

Clinical • Chronic Kidney Disease • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Nephrology • Oncology • Renal Disease • CD4 • CD8

Rapid viral suppression using integrase inhibitors during acute HIV-1 infection. (PubMed, J Antimicrob Chemother) - "INSTI-based ART during AHI resulted in rapid and sustained viral suppression. Over 96 weeks, weight increased in the INSTI-based cohort but was similar to weight increase in a historical NNRTI-based AHI cohort."

Journal • Human Immunodeficiency Virus • Infectious Disease

Complexities of Managing Chronic Hepatitis B in HIV: A Case of Acute Liver Injury Post-Medication Change (ACG 2024) - "On further history-taking, she reported a recent change in her HIV medication regimen from Efavirenz/Emtricitabine/Tenofovir to Dolutegravir/Rilpivirine in view of her worsening kidney function...Treatment with Entecavir and Lamivudine was initiated...As in our case, pegylated interferon or nucleos(t)ide analogues can be given to curb liver disease progression in affected individuals. Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024."

Clinical • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Liver Failure • Pain • CD4

A randomized controlled trial evaluating virologic and renal outcomes after switching from TDF/FTC/EFV to TDF/3TC/DTG (TLD) versus DTG+3TC in virologically suppressed Thai PWH – a pilot study (IDWeek 2024) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial. (PubMed, J Acquir Immune Defic Syndr) - "Markers of bone and renal toxicity did not differ significantly through week 50 postpartum among women randomized to start DTG + FTC/TAF or DTG + FTC/TDF or EFV/FTC/TDF in pregnancy."

Biomarker • Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Pediatrics • CD4

Metabolic, Mitochondrial, and Inflammatory Effects of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate in Asymptomatic Antiretroviral-Naïve People with HIV. (PubMed, Int J Mol Sci) - "This study aimed to comprehensively assess the metabolic, mitochondrial, and inflammatory effects of first-line efavirenz, emtricitabine, and tenofovir disoproxil fumarate (EFV/FTC/TDF) single-tablet regimen (STR) relative to untreated asymptomatic HIV infection. Inflammatory profile (TNFα, IL-6), ameliorated after treatment in accordance with viral reduction and the recovery of TNFα levels correlated to mtDNA cell restoration. Thus, although this regimen causes subclinical metabolic alterations, its antiviral and anti-inflammatory properties may be associated with partial improvement in mitochondrial function."

Journal • Human Immunodeficiency Virus • Infectious Disease • IL6 • TNFA

Brief communication: The rate of switching from first-line to second-line antiretroviral therapy among people living with HIV in Aden City, Yemen. (PubMed, AIDS Res Ther) - "The study highlights key factors associated with switching to second-line ART in Yemen, emphasizing the need for targeted interventions and continuous monitoring to enhance treatment outcomes. These findings are consistent with regional data from other resource-limited settings."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Enhancing HIV care: rapid antiretroviral therapy initiation in a community-based organization clinic in Kuala Lumpur, Malaysia (AIDS 2024) - "The majority, 96.9% initiated TDF/FTC/EFV, in line with our national guideline. The study demonstrates the feasibility of rapid ART initiation through a CBO-led clinic in Malaysia. Efforts to enhance clinic services are warranted to improve timely ART initiation, aligning with updated WHO guidelines including Bactrim and ART initiation on same time, and providing financial assistance for rapid ART initiation before referring to government facilities."

Human Immunodeficiency Virus • Infectious Disease • CD4